Last reviewed · How we verify
JAB-23E73
At a glance
| Generic name | JAB-23E73 |
|---|---|
| Sponsor | Jacobio Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration (PHASE1, PHASE2)
- JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JAB-23E73 CI brief — competitive landscape report
- JAB-23E73 updates RSS · CI watch RSS
- Jacobio Pharmaceuticals Co., Ltd. portfolio CI